pulmonologyadvisor3d
Tezspire Reduces Nasal Congestion and Polyp Size in Chronic Rhinosinusitis
Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.
FiercePharma6d
AstraZeneca, Amgen's Tezspire scores in rhinosinusitis study
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
EuropaWire6d
Tezspire Shows Promise in Reducing Nasal Polyp Symptoms in Phase III Trial for Chronic Rhinosinusitis
(IN BRIEF) A Phase III trial of Tezspire (tezepelumab) by AstraZeneca and Amgen has shown significant benefits for patients ...
Pharmaceutical Technology6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
Yahoo Finance6d
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
WILMINGTON, Del., November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) ...
AstraZeneca’s Tezspire Shows Promise in Phase III Trial
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, ...
Buy6d
AstraZeneca touts positive results from nasal polyp treatment study
(Alliance News) - AstraZeneca PLC on Friday said it received positive results from a trial of Tezspire as a treatment for chronic rhinosinusitis with nasal polyps.